{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:33:15Z","timestamp":1791181995551,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"26","license":[{"start":{"date-parts":[[2006,12,18]],"date-time":"2006-12-18T00:00:00Z","timestamp":1166400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,12,18]],"date-time":"2006-12-18T00:00:00Z","timestamp":1166400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2007,5,31]]},"DOI":"10.1038\/sj.onc.1210159","type":"journal-article","created":{"date-parts":[[2006,12,18]],"date-time":"2006-12-18T10:01:20Z","timestamp":1166436080000},"page":"3904-3908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate"],"prefix":"10.1038","volume":"26","author":[{"given":"O","family":"Kosmider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Moreau-Gachelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,12,18]]},"reference":[{"key":"BF1210159_CR1","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","volume":"103","author":"C Akin","year":"2004","unstructured":"Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD . (2004). A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103: 3222\u20133225.","journal-title":"Blood"},{"key":"BF1210159_CR2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V95.2.726","volume":"95","author":"A Beghini","year":"2000","unstructured":"Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E et al. (2000). C-kit mutations in core binding factor leukemias. Blood 95: 726\u2013727.","journal-title":"Blood"},{"key":"BF1210159_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ijc.11025","volume":"105","author":"H Chen","year":"2003","unstructured":"Chen H, Isozaki K, Kinoshita K, Ohashi A, Shinomura Y, Matsuzawa Y et al. (2003). Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int J Cancer 105: 130\u2013135.","journal-title":"Int J Cancer"},{"key":"BF1210159_CR4","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1182\/blood-2002-10-2998","volume":"102","author":"W Fiedler","year":"2003","unstructured":"Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U et al. (2003). A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102: 2763\u20132767.","journal-title":"Blood"},{"key":"BF1210159_CR5","first-page":"99","volume":"59","author":"TA Fong","year":"1999","unstructured":"Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ et al. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99\u2013106.","journal-title":"Cancer Res"},{"key":"BF1210159_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1182\/blood-2002-10-3023","volume":"102","author":"FJ Giles","year":"2003","unstructured":"Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL et al. (2003). SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102: 795\u2013801.","journal-title":"Blood"},{"key":"BF1210159_CR7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","volume":"96","author":"MC Heinrich","year":"2000","unstructured":"Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ . (2000). Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925\u2013932.","journal-title":"Blood"},{"key":"BF1210159_CR8","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1158\/1078-0432.CCR-04-0157","volume":"10","author":"JV Heymach","year":"2004","unstructured":"Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D et al. (2004). Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10: 5732\u20135740.","journal-title":"Clin Cancer Res"},{"key":"BF1210159_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577\u2013580.","journal-title":"Science"},{"key":"BF1210159_CR10","first-page":"295","volume":"1","author":"T Itokawa","year":"2002","unstructured":"Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, Yamada Y et al. (2002). Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther 1: 295\u2013302.","journal-title":"Mol Cancer Ther"},{"key":"BF1210159_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ccr.2005.11.009","volume":"8","author":"O Kosmider","year":"2005","unstructured":"Kosmider O, Denis N, Lacout C, Vainchenker W, Dubreuil P, Moreau-Gachelin F . (2005). Kit-activating mutations cooperate with Spi-1\/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell 8: 467\u2013478.","journal-title":"Cancer Cell"},{"key":"BF1210159_CR12","first-page":"3660","volume":"61","author":"GW Krystal","year":"2001","unstructured":"Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L et al. (2001). Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 61: 3660\u20133668.","journal-title":"Cancer Res"},{"key":"BF1210159_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1634\/stemcells.2004-0117","volume":"23","author":"J Lennartsson","year":"2005","unstructured":"Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R . (2005). Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23: 16\u201343.","journal-title":"Stem Cells"},{"key":"BF1210159_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/ng0396-312","volume":"12","author":"BJ Longley","year":"1996","unstructured":"Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG et al. (1996). Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12: 312\u2013314.","journal-title":"Nat Genet"},{"key":"BF1210159_CR15","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","volume":"99","author":"Y Ma","year":"2002","unstructured":"Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH et al. (2002). The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99: 1741\u20131744.","journal-title":"Blood"},{"key":"BF1210159_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood.V98.1.241","volume":"98","author":"RM Mesters","year":"2001","unstructured":"Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M et al. (2001). Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 98: 241\u2013243.","journal-title":"Blood"},{"key":"BF1210159_CR17","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1128\/MCB.16.5.2453","volume":"16","author":"F Moreau-Gachelin","year":"1996","unstructured":"Moreau-Gachelin F, Wendling F, Molina T, Denis N, Titeux M, Grimber G et al. (1996). Spi-1\/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol 16: 2453\u20132463.","journal-title":"Mol Cell Biol"},{"key":"BF1210159_CR18","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood.V97.11.3559","volume":"97","author":"ZQ Ning","year":"2001","unstructured":"Ning ZQ, Li J, Arceci RJ . (2001). Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 97: 3559\u20133567.","journal-title":"Blood"},{"key":"BF1210159_CR19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.leukres.2003.11.004","volume":"28","author":"AM O'Farrell","year":"2004","unstructured":"O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W et al. (2004). Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res 28: 679\u2013689.","journal-title":"Leuk Res"},{"key":"BF1210159_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x","volume":"96","author":"JM Pignon","year":"1997","unstructured":"Pignon JM, Giraudier S, Duquesnoy P, Jouault H, Imbert M, Vainchenker W et al. (1997). A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 96: 374\u2013376.","journal-title":"Br J Haematol"},{"key":"BF1210159_CR21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1182\/blood.V97.5.1413","volume":"97","author":"BD Smolich","year":"2001","unstructured":"Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM . (2001). The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 97: 1413\u20131421.","journal-title":"Blood"},{"key":"BF1210159_CR22","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1073\/pnas.0408831102","volume":"102","author":"YY Wang","year":"2005","unstructured":"Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX et al. (2005). AML1-ETO and C-KIT mutation\/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 102: 1104\u20131109.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1210159_CR23","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1182\/blood-2002-02-0531","volume":"100","author":"KW Yee","year":"2002","unstructured":"Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL et al. (2002). SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 100: 2941\u20132949.","journal-title":"Blood"},{"key":"BF1210159_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/sj.onc.1206120","volume":"22","author":"Y Zermati","year":"2003","unstructured":"Zermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, Casteran N et al. (2003). Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22: 660\u2013664.","journal-title":"Oncogene"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1210159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1210159","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1210159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T09:51:39Z","timestamp":1647942699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1210159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,18]]},"references-count":24,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2007,5,31]]}},"alternative-id":["BF1210159"],"URL":"https:\/\/doi.org\/10.1038\/sj.onc.1210159","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,18]]},"assertion":[{"value":"7 September 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}